Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
08 2021
Historique:
revised: 09 04 2021
received: 10 03 2021
accepted: 30 04 2021
pubmed: 10 5 2021
medline: 3 8 2021
entrez: 9 5 2021
Statut: ppublish

Résumé

Secondary to tumour necrosis factor-alpha induced protein 3 (TNFAIP3) mutations, A20 haploinsufficiency (HA20) is a recently described autoinflammatory disease with clinical features similar to those of Behçet's and Crohn's diseases but with a constantly expanding clinical spectrum. Here, we describe HA20 liver involvement in three new patients from the same family. We retrospectively assessed clinical, biological and/or histological findings for eight patients over three generations of the same family with heterozygous mutations in the TNFAIP3 gene (c.259C > T, p.Arg87*). The eight patients exhibited the following: aphthous ulcers (8/8, bipolar in 7), autoimmune features (6/8, including 5 with definitive autoimmune disease diagnoses, ie, type I diabetes, Hashimoto thyroiditis, pernicious anaemia, and/or 5 with antinuclear antibodies ≥320), pustulosis/folliculitis (5/8), abdominal pain (4/8), arthralgia (3/8), enlarged cervical lymph nodes (3/8) and pericarditis (1/8). In addition, three patients (twin sisters and their grandmother aged 23 and 70 years, respectively) exhibited persistent mild hepatic cytolysis associated with splenomegaly (n = 3), hepatomegaly (n = 1) and/or liver atrophy (n = 1) on echography. We could not detect any other causes of chronic liver diseases. Liver biopsies from three patients displayed hepatic fibrosis, hepatocyte injury and/or CD4 This study reinforces the dual involvement of innate and adaptive immunity in HA20 according to both acute and chronic injury and the organ involved and widens its clinical spectrum to include chronic hepatic involvement.

Sections du résumé

BACKGROUND & AIMS
Secondary to tumour necrosis factor-alpha induced protein 3 (TNFAIP3) mutations, A20 haploinsufficiency (HA20) is a recently described autoinflammatory disease with clinical features similar to those of Behçet's and Crohn's diseases but with a constantly expanding clinical spectrum. Here, we describe HA20 liver involvement in three new patients from the same family.
METHODS
We retrospectively assessed clinical, biological and/or histological findings for eight patients over three generations of the same family with heterozygous mutations in the TNFAIP3 gene (c.259C > T, p.Arg87*).
RESULTS
The eight patients exhibited the following: aphthous ulcers (8/8, bipolar in 7), autoimmune features (6/8, including 5 with definitive autoimmune disease diagnoses, ie, type I diabetes, Hashimoto thyroiditis, pernicious anaemia, and/or 5 with antinuclear antibodies ≥320), pustulosis/folliculitis (5/8), abdominal pain (4/8), arthralgia (3/8), enlarged cervical lymph nodes (3/8) and pericarditis (1/8). In addition, three patients (twin sisters and their grandmother aged 23 and 70 years, respectively) exhibited persistent mild hepatic cytolysis associated with splenomegaly (n = 3), hepatomegaly (n = 1) and/or liver atrophy (n = 1) on echography. We could not detect any other causes of chronic liver diseases. Liver biopsies from three patients displayed hepatic fibrosis, hepatocyte injury and/or CD4
CONCLUSIONS
This study reinforces the dual involvement of innate and adaptive immunity in HA20 according to both acute and chronic injury and the organ involved and widens its clinical spectrum to include chronic hepatic involvement.

Identifiants

pubmed: 33966343
doi: 10.1111/liv.14935
doi:

Substances chimiques

NF-kappa B 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1894-1900

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48:67-73.
Aeschlimann FA, Batu ED, Canna SW, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77:728-735.
Berteau F, Rouviere B, Delluc A, et al. Autosomic dominant familial Behçet disease and haploinsufficiency A20: a review of the literature. Autoimmun Rev. 2018;17:809-815.
Tsuchida N, Kirino Y, Soejima Y, et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease. Arthritis Res Ther. 2019;21:137.
Kadowaki T, Ohnishi H, Kawamoto N, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol. 2018;141(4):1485-1488.e11.
Li G-M, Liu H-M, Guan W-Z, Xu H, Wu B-B, Sun L. Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report. BMC Med Genet. 2019;20:124.
Takagi M, Ogata S, Ueno H, et al. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2017;139:1914-1922.
Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:1059-1061.
Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40:1062-1064.
Adrianto I, Wen F, Templeton A, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43:253-258.
Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007;39:1477-1482.
Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet. 2007;39:1431-1433.
Stuart P, Nair R, Tsoi L, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97:816-836.
Hautala T, Vähäsalo P, Kuismin O, et al. A family with A20 haploinsufficiency presenting with novel clinical manifestations and challenges for treatment. J Clin Rheumatol. 2020.
Schwartz DM, Blackstone SA, Sampaio-Moura N, et al. Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20. Ann Rheum Dis. 2020;79:429-431.
Jeanson L, Thomas L, Copin B, et al. Mutations in GAS8, a gene encoding a nexin-dynein regulatory complex subunit, cause primary ciliary dyskinesia with axonemal disorganization. Hum Mutat. 2016;37:776-785.
Duncan CJA, Dinnigan E, Theobald R, et al. Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20). Ann Rheum Dis. 2018;77:783-786.
Gans MD, Wang H, Moura NS, Aksentijevich I, Rubinstein A. A20 haploinsufficiency presenting with a combined immunodeficiency. J Clin Immunol. 2020;40:1041-1044.
He T, Huang Y, Luo Y, et al. Haploinsufficiency of A20 due to novel mutations in TNFAIP3. J Clin Immunol. 2020;40:741-751.
Kim H-Y, Song JY, Kim W-I, et al. The first case of an infant with familial A20 haploinsufficiency in Korea. J Korean Med Sci. 2020;35:e252.
Taniguchi K, Inoue M, Arai K, et al. Novel TNFAIP3 microdeletion in a girl with infantile-onset inflammatory bowel disease complicated by a severe perianal lesion. Hum Genome Var. 2021;8:1.
Chen YU, Ye Z, Chen L, et al. Association of clinical phenotypes in haploinsufficiency A20 (HA20) with disrupted domains of A20. Front Immunol. 2020;11:574992.
Tavares RM, Turer EE, Liu CL, et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010;33:181-191.
Song X-T, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen S-Y. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med. 2008;14:258-265.
Kool M, van Loo G, Waelput W, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011;35:82-96.
Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289:2350-2354.
Giordano M, Roncagalli R, Bourdely P, et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci USA. 2014;111:11115-11120.

Auteurs

Samuel Deshayes (S)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
Normandie Univ, UNICAEN, Caen, France.

Céline Bazille (C)

Department of Pathology, CHU de Caen Normandie, Caen, France.

Elma El Khouri (E)

Department of Genetics, Sorbonne Université, UPMC University, Paris, France.

Isabelle Kone-Paut (I)

Department of Pediatric Rheumatology, Bicêtre Hospital, AP-HP, University of Paris Sud Saclay, CEREMAIA, Le Kremlin-Bicêtre, France.

Irina Giurgea (I)

Department of Genetics, Sorbonne Université, UPMC University, Paris, France.

Sophie Georgin-Lavialle (S)

Department of Internal Medicine, Sorbonne Université, UPMC University, CEREMAIA, Paris, France.

Nicolas Martin Silva (N)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Anaël Dumont (A)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
Normandie Univ, UNICAEN, Caen, France.

Isabelle Ollivier (I)

Department of Hepatogastroenterology, CHU de Caen Normandie, Caen, France.

Serge Amselem (S)

Department of Genetics, Sorbonne Université, UPMC University, Paris, France.

Hubert de Boysson (H)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
Normandie Univ, UNICAEN, Caen, France.

Achille Aouba (A)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
Normandie Univ, UNICAEN, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH